Market Overview

UPDATE: Jefferies Resumes Coverage On Sequenom On Revised Revenue/EPS Forecasts

Share:
Related SQNM
Sequenom Names Dirk van den Boom as President and CEO
Sequenom To Explore The Clinical Utility Of A Novel Liquid Biopsy Assay In Melanoma Patients In Collaboration With University Of Colorado Denver
Illumina taps former Google exec to head startup developing early-stage cancer test (Seeking Alpha)

In a report published Thursday, Jefferies analyst Brandon Couillard resumed coverage on Sequenom (NASDAQ; SQNM) with a Buy rating and $5.00 price target, up from $4.50.

In the report, Jefferies noted, “We are resuming our rating on SQNM with a Buy and $5 PT (Restricted 9/23/13). Our revised revenue and EPS forecasts reflect the effects of SQNM's recent divestiture of its Biosciences unit, as well as expectations for a profitability & cash flow inflection in 4Q14.”

Sequenom closed on Wednesday at $3.97.

Latest Ratings for SQNM

DateFirmActionFromTo
Sep 2015JefferiesDowngradesBuyHold
Sep 2015William BlairDowngradesMarket Perform
Sep 2015Ladenburg ThalmannDowngradesSell

View More Analyst Ratings for SQNM
View the Latest Analyst Ratings

Posted-In: Brandon Couillard JefferiesAnalyst Color Initiation Analyst Ratings

 

Related Articles (SQNM)

View Comments and Join the Discussion!

Get Benzinga's Newsletters